Pyruvate Kinase M2: A New Biomarker for the Early Detection of Diabetes-Induced Nephropathy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032683 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Yeon Su Park und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korean Government.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetic nephropathy (DN) is a common complication of diabetes. DN progresses to end-stage renal disease, which has a high mortality rate. Current research is focused on identifying non-invasive potential biomarkers in the early stage of DN. We previously indicated that pyruvate kinase M2 (PKM2) is excreted in the urine of rats after cisplatin-induced acute kidney injury (AKI). However, it has not been reported whether PKM2 can be used as a biomarker to diagnose DN. Therefore, we try to compare whether the protein PKM2 can be detected in the urine samples from diabetic patients as shown in the results of DN models. In this study, high-fat diet (HFD)-induced Zucker diabetic fatty (ZDF) rats were used for DN phenotyping. After 19 weeks of receiving a HFD, the DN model’s blood glucose, blood urea nitrogen, and serum creatinine levels were significantly increased; severe tubular and glomerular damages were also noted. The following protein-based biomarkers were increased in the urine of these models: kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and PKM2. PKM2 had the earliest detection rate. In the urine samples of patients, PKM2 protein was highly detected in the urine of diabetic patients but was not excreted in the urine of normal subjects. Therefore, PKM2 was selected as the new biomarker for the early diagnosis of DN. Our results reflect current knowledge on the role of PKM2 in DN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
- St. Mark's School, 25 Marlboro Rd, Southborough, MA 01772, USA.
ORCID-Profile: Joo Hee Han, Hyung Sik Kim
Förderung
- National Research Foundation of Korea (NRF) grant funded by the Korean Government
Zitieren
APA
Park, Y. S., Han, J. H., Park, J. H., Choi, J. S., Kim, S. H., & Kim, H. S. (2023). Pyruvate Kinase M2: A New Biomarker for the Early Detection of Diabetes-Induced Nephropathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032683
Vancouver
Park YS, Han JH, Park JH, Choi JS, Kim SH, Kim HS. Pyruvate Kinase M2: A New Biomarker for the Early Detection of Diabetes-Induced Nephropathy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032683
BibTeX
@article{Park2023,
author = {Park, Yeon Su and Han, Joo Hee and Park, Jae Hyeon and Choi, Ji Soo and Kim, Seung Hyeon and Kim, Hyung Sik},
title = {Pyruvate Kinase M2: A New Biomarker for the Early Detection of Diabetes-Induced Nephropathy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032683}
}
EUVIMED